ABUS vs IBM · P/E 5.4, rev $6.2M vs P/E 25, rev $67.53B
Arbutus Biopharma Corp (ABUS) versus International Business Machines (IBM) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
International Business Machines (IBM) is a information technology services company listed on US. It is led by Arvind Krishna.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported IBM revenue for 2025-12-31 was $67.53B. Net income was $10.59B. Revenue was up 7.6% from 2024-12-31 to 2025-12-31. IBM currently screens at market cap $267.72B and trailing P/E 25.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. IBM currently screens at market cap $267.72B and trailing P/E 25.2.
Not investment advice. Open the ABUS and IBM stock pages for the full models.
Not investment advice.